Eloralintide

What Is Eloralintide?

Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist developed by Eli Lilly for once-weekly dosing. Amylin is a pancreatic peptide that reduces appetite and slows gastric emptying through pathways distinct from GLP-1. In a 48-week phase 2 trial published in The Lancet, mean weight reduction ranged from 9.5% to 20.1% across dose groups versus 0.4% with placebo.

Research Context

• Selective amylin receptor agonism and hypothalamic appetite signaling
• Once-weekly dosing from an extended half-life
• Gastric emptying modulation and postprandial glucose control
• Combination with incretin agonists such as tirzepatide in ongoing trials